Stephen Liu, Director of Thoracic Oncology and Associate Professor of Medicine at Georgetown University, shared a post on X:
“Phase III study of 1L limertinib (3G TKI) vs gefitinib in NSCLC.
Limertinib superior with PFS 20.7m vs 9.7m (HR 0.44), same rate of G3+ TRAEs. Good to have more agents but I do think the days of 1G TKI control arms have passed…”
Title: Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Authors: Yuankai Shi, Lin Wu, Yinghua Ji, Gongyan Chen, Baolan Li, Minghong Bi, Runxiang Yang, Liyun Miao, Guojun Zhang, Hongjun Gao, Longhua Sun, Mingjun Zhang, Shundong Cang, Meili Sun, Wenxiu Yao, Zhijie Pan, Jiuwei Cui, Yi Xiao, Qiming Wang
You can read the Full Article on The Lancet Respiratory Medicine
More posts featuring Stephen Liu.